Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Bristol Myers Squibb (BMS) has shared promising results from a late-stage study of its dual immunotherapy combination in ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease ...

Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...

Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

This mini-review highlights the latest advancements in tumor immunotherapy, with a focus on cellular therapies, and addresses the resistance mechanisms that hinder their effectiveness in lung and ...